BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 29406853)

  • 1. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
    Bansilal S; Bonaca MP; Cornel JH; Storey RF; Bhatt DL; Steg PG; Im K; Murphy SA; Angiolillo DJ; Kiss RG; Parkhomenko AN; Lopez-Sendon J; Isaza D; Goudev A; Kontny F; Held P; Jensen EC; Braunwald E; Sabatine MS; Oude Ophuis AJ
    J Am Coll Cardiol; 2018 Feb; 71(5):489-496. PubMed ID: 29406853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
    Bhatt DL; Bonaca MP; Bansilal S; Angiolillo DJ; Cohen M; Storey RF; Im K; Murphy SA; Held P; Braunwald E; Sabatine MS; Steg PG
    J Am Coll Cardiol; 2016 Jun; 67(23):2732-2740. PubMed ID: 27046160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.
    Bergmark BA; Bhatt DL; Steg PG; Budaj A; Storey RF; Gurmu Y; Kuder JF; Im K; Magnani G; Oude Ophuis T; Hamm C; Špinar J; Kiss RG; Van de Werf FJ; Montalescot G; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
    J Am Heart Assoc; 2021 Sep; 10(17):e020446. PubMed ID: 34423649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
    Magnani G; Storey RF; Steg G; Bhatt DL; Cohen M; Kuder J; Im K; Aylward P; Ardissino D; Isaza D; Parkhomenko A; Goudev AR; Dellborg M; Kontny F; Corbalan R; Medina F; Jensen EC; Held P; Braunwald E; Sabatine MS; Bonaca MP
    Eur Heart J; 2016 Jan; 37(4):400-8. PubMed ID: 26443023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
    Furtado RHM; Nicolau JC; Magnani G; Im K; Bhatt DL; Storey RF; Steg PG; Spinar J; Budaj A; Kontny F; Corbalan R; Kiss RG; Abola MT; Johanson P; Jensen EC; Braunwald E; Sabatine MS; Bonaca MP
    Eur Heart J; 2020 May; 41(17):1625-1632. PubMed ID: 31811715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
    Gencer B; Li XS; Gurmu Y; Bonaca MP; Morrow DA; Cohen M; Bhatt DL; Steg PG; Storey RF; Johanson P; Wang Z; Hazen SL; Sabatine MS
    J Am Heart Assoc; 2020 May; 9(10):e015331. PubMed ID: 32366163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
    Magnuson EA; Li H; Wang K; Vilain K; Shafiq A; Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Braunwald E; Sabatine MS; Cohen DJ;
    J Am Coll Cardiol; 2017 Aug; 70(5):527-538. PubMed ID: 28750695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
    N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
    Dellborg M; Bonaca MP; Storey RF; Steg PG; Im KA; Cohen M; Bhatt DL; Oude Ophuis T; Budaj A; Hamm C; Spinar J; Kiss RG; Lopez-Sendon J; Kamensky G; Van de Werf F; Ardissino D; Kontny F; Montalescot G; Johanson P; Bengtsson O; Himmelmann A; Braunwald E; Sabatine MS
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):200-206. PubMed ID: 31218354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
    Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
    Bonaca MP; Bhatt DL; Steg PG; Storey RF; Cohen M; Im K; Oude Ophuis T; Budaj A; Goto S; López-Sendón J; Diaz R; Dalby A; Van de Werf F; Ardissino D; Montalescot G; Aylward P; Magnani G; Jensen EC; Held P; Braunwald E; Sabatine MS
    Eur Heart J; 2016 Apr; 37(14):1133-42. PubMed ID: 26491109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.
    Bonaca MP; Wiviott SD; Morrow DA; Steg PG; Hamm C; Bhatt DL; Storey RF; Cohen M; Kuder J; Im K; Magnani G; Budaj A; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Diaz R; Van de Werf F; Corbalán R; Goudev A; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Heart Assoc; 2018 Nov; 7(22):e009260. PubMed ID: 30571502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health.
    Ahn JH; Ahn Y; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim MC; Hwang JY; Yoon JH; Seong IW; Hur SH; Oh SK;
    J Cardiol; 2020 May; 75(5):478-484. PubMed ID: 31859138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
    Bonaca MP; Storey RF; Theroux P; Steg PG; Bhatt DL; Cohen MC; Im K; Murphy SA; Magnani G; Ophuis TO; Rudah M; Parkhomenko A; Isaza D; Kamensky G; Goudev A; Montalescot G; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2017 Sep; 70(11):1368-1375. PubMed ID: 28882235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of ticagrelor in patients with prior myocardial infarction.
    Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Jensen EC; Magnani G; Bansilal S; Fish MP; Im K; Bengtsson O; Oude Ophuis T; Budaj A; Theroux P; Ruda M; Hamm C; Goto S; Spinar J; Nicolau JC; Kiss RG; Murphy SA; Wiviott SD; Held P; Braunwald E; Sabatine MS;
    N Engl J Med; 2015 May; 372(19):1791-800. PubMed ID: 25773268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
    Furtado RHM; Venkateswaran RV; Nicolau JC; Gurmu Y; Bhatt DL; Storey RF; Steg PG; Magnani G; Goto S; Dellborg M; Kamensky G; Isaza D; Aylward P; Johanson P; Bonaca MP
    J Am Heart Assoc; 2020 May; 9(10):e015785. PubMed ID: 32410485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.